Comparative Pharmacology
Head-to-head clinical analysis: GVS versus PAROMOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GVS versus PAROMOMYCIN SULFATE.
GVS vs PAROMOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GVS is not a recognized drug. No mechanism of action available.
Paromomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in susceptible bacteria. It also has direct amebicidal activity against Entamoeba histolytica by inhibiting protein synthesis.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
25-35 mg/kg/day orally in 3 divided doses for 5-10 days for intestinal amebiasis; 1 g orally every 8 hours for 7 days for cryptosporidiosis.
None Documented
None Documented
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 2–3 hours in normal renal function; extends to 24–48 hours or longer in severe renal impairment, necessitating dose adjustment.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Primarily renal excretion of unchanged drug via glomerular filtration; >90% of absorbed dose excreted in urine within 24 hours; negligible biliary/fecal elimination.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic